Unicycive Therapeutics Stock Buy Hold or Sell Recommendation
| UNCY Stock | USD 0.53 0.02 3.92% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Unicycive Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Unicycive Therapeutics given historical horizon and risk tolerance towards Unicycive Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Unicycive Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Unicycive Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide. In addition, we conduct extensive research on individual companies such as Unicycive and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Unicycive |
Execute Unicycive Therapeutics Buy or Sell Advice
The Unicycive recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Unicycive Therapeutics. Macroaxis does not own or have any residual interests in Unicycive Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Unicycive Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Unicycive Therapeutics Trading Alerts and Improvement Suggestions
| Unicycive Therapeutics is way too risky over 90 days horizon | |
| Unicycive Therapeutics has some characteristics of a very speculative penny stock | |
| Unicycive Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 675 K. Net Loss for the year was (30.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Unicycive Therapeutics currently holds about 10.57 M in cash with (18.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Significant Stake Acquired by Biotechnology Value Fund L P in Unicycive Therapeutics Inc |
Unicycive Therapeutics Returns Distribution Density
The distribution of Unicycive Therapeutics' historical returns is an attempt to chart the uncertainty of Unicycive Therapeutics' future price movements. The chart of the probability distribution of Unicycive Therapeutics daily returns describes the distribution of returns around its average expected value. We use Unicycive Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Unicycive Therapeutics returns is essential to provide solid investment advice for Unicycive Therapeutics.
| Mean Return | 0.54 | Value At Risk | -7.41 | Potential Upside | 9.76 | Standard Deviation | 5.34 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Unicycive Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Unicycive Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Unicycive Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Unicycive Therapeutics back and forth among themselves.
| Shares | State Street Corp | 2024-06-30 | 43.9 K | Northern Trust Corp | 2024-09-30 | 24 K | Captrust Financial Advisors | 2024-06-30 | 18.8 K | Tower Research Capital Llc | 2024-06-30 | 18.5 K | Tandem Capital Management Corp | 2024-09-30 | 15.5 K | Virtu Financial Llc | 2024-06-30 | 11.1 K | Scientech Research Llc | 2024-06-30 | 11 K | Redwood Wealth Management Group Llc | 2024-06-30 | 3 K | Bank Of America Corp | 2024-06-30 | 223 | Logos Global Management Lp | 2024-06-30 | 6.9 M | Nantahala Capital Management, Llc | 2024-06-30 | 5.6 M |
Unicycive Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (10K) | (15K) | 16.6M | (16.1M) | 9.2M | 9.7M | |
| Net Income | (2.2M) | (2.3M) | (10.0M) | (18.1M) | (30.5M) | (29.0M) | |
| End Period Cash Flow | 15K | 147K | 16.6M | 455K | 9.7M | 4.9M |
Unicycive Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Unicycive Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Unicycive Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Unicycive stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.39 | |
β | Beta against Dow Jones | 1.67 | |
σ | Overall volatility | 5.45 | |
Ir | Information ratio | 0.08 |
Unicycive Therapeutics Volatility Alert
Unicycive Therapeutics exhibits above-average semi-deviation for your current time horizon. Unicycive Therapeutics is a potential penny stock. Although Unicycive Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Unicycive Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Unicycive instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Unicycive Therapeutics Fundamentals Vs Peers
Comparing Unicycive Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Unicycive Therapeutics' direct or indirect competition across all of the common fundamentals between Unicycive Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Unicycive Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Unicycive Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Unicycive Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Unicycive Therapeutics to competition |
| Fundamentals | Unicycive Therapeutics | Peer Average |
| Return On Equity | -1.22 | -0.31 |
| Return On Asset | -0.53 | -0.14 |
| Current Valuation | 21.33 M | 16.62 B |
| Shares Outstanding | 103.8 M | 571.82 M |
| Shares Owned By Insiders | 6.73 % | 10.09 % |
| Shares Owned By Institutions | 38.20 % | 39.21 % |
| Number Of Shares Shorted | 1.05 M | 4.71 M |
| Price To Book | 1.90 X | 9.51 X |
| Price To Sales | 62.82 X | 11.42 X |
| Revenue | 675 K | 9.43 B |
| EBITDA | (30.18 M) | 3.9 B |
| Net Income | (30.54 M) | 570.98 M |
| Cash And Equivalents | 10.57 M | 2.7 B |
| Cash Per Share | 0.70 X | 5.01 X |
| Total Debt | 811 K | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 4.43 X | 2.16 X |
| Book Value Per Share | (0.11) X | 1.93 K |
| Cash Flow From Operations | (18.28 M) | 971.22 M |
| Short Ratio | 0.74 X | 4.00 X |
| Earnings Per Share | (0.46) X | 3.12 X |
| Target Price | 5.5 | |
| Number Of Employees | 14 | 18.84 K |
| Beta | 2.29 | -0.15 |
| Market Capitalization | 52.87 M | 19.03 B |
| Total Asset | 14.19 M | 29.47 B |
| Retained Earnings | (64.54 M) | 9.33 B |
| Working Capital | (4.13 M) | 1.48 B |
| Net Asset | 14.19 M |
Note: Acquisition by Aggarwal Gaurav of 5500000 shares of Unicycive Therapeutics at 1000.0 subject to Rule 16b-3 [view details]
Unicycive Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Unicycive . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Unicycive Therapeutics Buy or Sell Advice
When is the right time to buy or sell Unicycive Therapeutics? Buying financial instruments such as Unicycive Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Unicycive Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.